Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Osimertinib in NSCLC With Uncommon EGFR Mutations
NCT05546866Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Feb 2023
- Primary completion
- Jun 2029
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Primary endpoint: Disease-Free Survival at 3 years. Started Feb 2023; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05546866.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05546866.